Earendil Labs secured a large discovery collaboration with Genentech, with the agreement framed as a $1.5 billion collaboration focused on developing bispecific antibody therapeutics for oncology. The companies’ deal marks Earendil’s second major collaboration of the year, signaling continued pharma interest in AI-led protein design capabilities. The initiative leverages Earendil’s AI platform for discovery, while Genentech provides development and clinical integration resources. The article positions the program around generating and maturing bispecific candidates, an area where oncology remains a top demand driver. For biotech vendors, the size of the collaboration is notable: discovery-stage deals at this scale typically reflect confidence in both technical differentiation and downstream development feasibility. For Genentech, the partnership adds pipeline optionality in a modality segment that remains crowded but still competitive for differentiated binders, affinity/avidity profiles, and developability outcomes.